Skip to main content
Erschienen in: Journal of Neurology 1/2011

01.01.2011 | Original Communication

Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter

verfasst von: Karl Strecker, Florian Wegner, Swen Hesse, Georg-Alexander Becker, Marianne Patt, Philipp M. Meyer, Donald Lobsien, Johannes Schwarz, Osama Sabri

Erschienen in: Journal of Neurology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Recent imaging and neuropathological studies indicate reduced serotonin transporter (SERT) in advanced Parkinson’s disease (PD). However, data on SERT in early PD patients are sparse. Following the hypothesis that the serotonergic system is damaged early in PD, the aim of our study was to investigate SERT availability by means of PET imaging. Since the loss of dopaminergic neurons is the pathologic hallmark of PD and SERT might be associated with psychiatric co-morbidity, we further sought to correlate SERT availability with the availability of dopamine transporter (DAT) and depressive or motor symptoms in early PD. We prospectively recruited nine early PD patients (4 female, 5 male; 42–76 years) and nine age matched healthy volunteers (5 female, 4 male; 42–72 years). Diagnosis of PD was confirmed by the UK brain bank criteria and DAT imaging. SERT availability was measured by means of [11C]DASB PET. For neuropsychiatric assessment done on the day of PET we applied UPDRS parts I, II and III, Beck’s Depression Inventory, Hamilton Rating Scale for Depression, Mini-Mental State Examination and Demtect. SERT was not reduced in any of 14 investigated regions of interest in the nine PD patients compared to healthy controls (p > 0.13). SERT was negatively associated with DAT in the striatum (r = −0.69; p = 0.04) but not within the midbrain. There was no correlation of SERT availability with depressive symptoms. No alteration of SERT binding in our patients suggests that the serotonergic system is remarkably preserved in early PD. Correlation with DAT might point to a compensatory regulation of the serotonergic system in early stages of PD.
Literatur
1.
Zurück zum Zitat Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA (2008) Spared caudal brainstem SERT binding in early Parkinson’s disease. J Cereb Blood Flow Metab 28:441–444CrossRefPubMed Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA (2008) Spared caudal brainstem SERT binding in early Parkinson’s disease. J Cereb Blood Flow Metab 28:441–444CrossRefPubMed
2.
Zurück zum Zitat Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ (2008) Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord 23:1776–1780CrossRefPubMed Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ (2008) Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord 23:1776–1780CrossRefPubMed
3.
Zurück zum Zitat Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925CrossRefPubMed Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925CrossRefPubMed
4.
Zurück zum Zitat Brucke T, Riederer P (1986) Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease. Wien Med Wochenschr 136:401–408PubMed Brucke T, Riederer P (1986) Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease. Wien Med Wochenschr 136:401–408PubMed
5.
Zurück zum Zitat Caretti V, Stoffers D, Winogrodzka A, Isaias IU, Costantino G, Pezzoli G, Ferrarese C, Antonini A, Wolters EC, Booij J (2008) Loss of thalamic serotonin transporters in early drug-naive Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study. J Neural Transm 115:721–729CrossRefPubMed Caretti V, Stoffers D, Winogrodzka A, Isaias IU, Costantino G, Pezzoli G, Ferrarese C, Antonini A, Wolters EC, Booij J (2008) Loss of thalamic serotonin transporters in early drug-naive Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study. J Neural Transm 115:721–729CrossRefPubMed
6.
Zurück zum Zitat Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819–1833CrossRefPubMed Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819–1833CrossRefPubMed
7.
Zurück zum Zitat de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefPubMed de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefPubMed
8.
Zurück zum Zitat Gaspar P, Febvret A, Colombo J (1993) Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96:100–106PubMed Gaspar P, Febvret A, Colombo J (1993) Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96:100–106PubMed
9.
Zurück zum Zitat Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol 14:523–528CrossRefPubMed Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol 14:523–528CrossRefPubMed
10.
Zurück zum Zitat Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res 510:104–107CrossRefPubMed Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res 510:104–107CrossRefPubMed
11.
Zurück zum Zitat Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199CrossRefPubMed Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199CrossRefPubMed
12.
Zurück zum Zitat Hensler JG, Ferry RC, Labow DM, Kovachich GB, Frazer A (1994) Quantitative autoradiography of the serotonin transporter to assess the distribution of serotonergic projections from the dorsal raphe nucleus. Synapse 17:1–15CrossRefPubMed Hensler JG, Ferry RC, Labow DM, Kovachich GB, Frazer A (1994) Quantitative autoradiography of the serotonin transporter to assess the distribution of serotonergic projections from the dorsal raphe nucleus. Synapse 17:1–15CrossRefPubMed
13.
Zurück zum Zitat Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O (2006) Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 113:1177–1190CrossRefPubMed Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O (2006) Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 113:1177–1190CrossRefPubMed
14.
Zurück zum Zitat Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, Oehlwein C, Barthel H, Schneider JP, Wegner F, Meyer P, Meixensberger J, Sabri O, Schwarz J (2008) Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson’s disease within one-year follow-up. J Neurol 255:1059–1066CrossRefPubMed Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, Oehlwein C, Barthel H, Schneider JP, Wegner F, Meyer P, Meixensberger J, Sabri O, Schwarz J (2008) Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson’s disease within one-year follow-up. J Neurol 255:1059–1066CrossRefPubMed
15.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMed Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMed
16.
Zurück zum Zitat Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112CrossRefPubMed Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096–1112CrossRefPubMed
17.
Zurück zum Zitat Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539CrossRefPubMed Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539CrossRefPubMed
18.
Zurück zum Zitat Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72:165–229PubMed Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72:165–229PubMed
19.
Zurück zum Zitat Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223–1229CrossRefPubMed Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223–1229CrossRefPubMed
20.
Zurück zum Zitat Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131PubMed Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131PubMed
21.
Zurück zum Zitat Kovacs GG, Kloppel S, Fischer I, Dorner S, Lindeck-Pozza E, Birner P, Botefur IC, Pilz P, Volk B, Budka H (2003) Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14:73–76CrossRefPubMed Kovacs GG, Kloppel S, Fischer I, Dorner S, Lindeck-Pozza E, Birner P, Botefur IC, Pilz P, Volk B, Budka H (2003) Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14:73–76CrossRefPubMed
22.
Zurück zum Zitat Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord 15:1221–1224CrossRefPubMed Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord 15:1221–1224CrossRefPubMed
23.
Zurück zum Zitat Mai JK, Paxinos G, Assheuer JK (2004) Atlas of the human brain, 2nd edn. Elsevier Academic Press, San Diego Mai JK, Paxinos G, Assheuer JK (2004) Atlas of the human brain, 2nd edn. Elsevier Academic Press, San Diego
24.
Zurück zum Zitat Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP (1996) [123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237PubMed Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP (1996) [123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237PubMed
25.
Zurück zum Zitat Mayeux R (1990) The “serotonin hypothesis” for depression in Parkinson’s disease. Adv Neurol 53:163–166PubMed Mayeux R (1990) The “serotonin hypothesis” for depression in Parkinson’s disease. Adv Neurol 53:163–166PubMed
26.
Zurück zum Zitat Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA (2004) Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61:1271–1279CrossRefPubMed Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA (2004) Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61:1271–1279CrossRefPubMed
27.
Zurück zum Zitat Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J (2009) Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66:866–877CrossRefPubMed Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J (2009) Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66:866–877CrossRefPubMed
28.
Zurück zum Zitat Mounayar S, Boulet S, Tande D, Jan C, Pessiglione M, Hirsch EC, Feger J, Savasta M, Francois C, Tremblay L (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130:2898–2914CrossRefPubMed Mounayar S, Boulet S, Tande D, Jan C, Pessiglione M, Hirsch EC, Feger J, Savasta M, Francois C, Tremblay L (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130:2898–2914CrossRefPubMed
29.
Zurück zum Zitat Naarding P, Leentjens AF, van Kooten F, Verhey FR (2002) Disease-specific properties of the rating scale for depression in patients with stroke, Alzheimer’s dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 14:329–334PubMed Naarding P, Leentjens AF, van Kooten F, Verhey FR (2002) Disease-specific properties of the rating scale for depression in patients with stroke, Alzheimer’s dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 14:329–334PubMed
30.
Zurück zum Zitat O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106CrossRefPubMed O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106CrossRefPubMed
31.
Zurück zum Zitat Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006) Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163:52–58CrossRefPubMed Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006) Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163:52–58CrossRefPubMed
32.
Zurück zum Zitat Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755CrossRefPubMed Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755CrossRefPubMed
33.
34.
Zurück zum Zitat Sawada M, Nagatsu T, Nagatsu I, Ito K, Iizuka R, Kondo T, Narabayashi H (1985) Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J Neural Transm 62:107–115CrossRefPubMed Sawada M, Nagatsu T, Nagatsu I, Ito K, Iizuka R, Kondo T, Narabayashi H (1985) Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J Neural Transm 62:107–115CrossRefPubMed
Metadaten
Titel
Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter
verfasst von
Karl Strecker
Florian Wegner
Swen Hesse
Georg-Alexander Becker
Marianne Patt
Philipp M. Meyer
Donald Lobsien
Johannes Schwarz
Osama Sabri
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 1/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5666-5

Weitere Artikel der Ausgabe 1/2011

Journal of Neurology 1/2011 Zur Ausgabe

Medical Progress in the Journal of Neurology

Advances in cerebrovascular disease research in the last year

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.